|
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an €30,000 fine over breaches in 2024. The committee found that Faron breached the Nasdaq First North Growth Rulebook for Issuers of Shares, regarding ‘the obligation to disclose inside information without undue delay in certain matters’. It also breached ‘good securities market practise’ regarding ‘certain public statements made in a media interview’. Faron notes that the committee dismissed two alleged breaches, including ‘importantly,’ the allegation that Faron had not organised its administration in the manner required for listed companies. ‘The company aims in all of its operations to accurate, explicit and timely communication following all the rules the company is obligated to follow,’ Faron says. ‘The company takes compliance with the rules very seriously and continuously implements actions to ensure compliance. The fine does not have a material impact on the company’s operations.’ Current stock price: 47.00 pence, down 0.8% in London on Friday 12-month change: down 57% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
